- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Lilly Launches Online Training for Patient Advocates
An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
An interactive training program designed “to help patient advocates better influence decisions related to access to new medicines” was launched today by Eli Lilly.
eMEET (Medicine Evaluation Educational Training) is designed to help patient advocates “navigate the complex world of medicines development, evaluation and assessment.”
It uses video presentations, animations and exercises to show how patients’ experiences are integrated into scientifically based HTA decisions, with training program modules focused on ‘the journey of a medicine’, ‘an introduction to HTA’, ‘HTA in practice’ and ‘patient advocacy group participation in HTA’.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
